Compare Eli Lilly And Co (LLY) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Eli Lilly And Co is far larger — about 1856.1× Direxion Daily FTSE China Bull 3x Shares's market cap, and Eli Lilly And Co pays a 0.59% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| LLY | YINN | |
|---|---|---|
Market Cap | $1.04T | $560.32M |
Volume | 3,064,878 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $52.69 |
52-Week Low | $799.57 | $21.45 |
Typical Hold Time | 93 Days | 25 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
YINN trades at $23.63, up 0.3% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. Moving averages indicate strong bearish momentum while oscillators remain neutral. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific fundamentals show limited available data.
The bearish technical setup and lack of clear fundamental metrics create uncertainty. Investment opportunity depends on broader market trends and China's economic developments, while risks include technical breakdown below support and regional economic volatility. Further fundamental disclosure is needed for comprehensive analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
